vaccinex.com (VCNX): Utang marang Ekuitas

Logo korporat perusahaan Vaccinex Inc (VCNX)

The price trend illustrated in this chart demonstrates a debt-to-equity ratio of 0.00, highlighting a severe liquidity shortage and forced share issuances by Vaccinex, Inc. (VCNX). Vaccinex, Inc. (VCNX) is developing immune therapies for oncology and dementia while facing the threat of failed tests for Huntington's disease. Growth potential is based on licensing patents to global partners to generate royalties.

VCNX: Rasio Total Utang marang Ekuitas Vaccinex 04.07.2022 - 28.12.2024

Rincian metrik komprehensif lan analitis Vaccinex Inc (VCNX)

- rega lan prakiraan konsensus rega:
Bagan rega Vaccinex|VCNX - Rata-rata rega prakiraan
- data kapitalisasi bursa:
Nilai pasar Vaccinex|VCNX - Nilai Bisnis
- rincian nilai buku perusahaan:
Nilai Buku saben Saham Vaccinex|VCNX - Aset Bersih Perusahaan|Rasio Nilai Pasar marang Nilai Buku vaccinex.com|VCNX - Aset Perusahaan
- statistik kawajiban utang lan likuiditas:
Utang marang Ekuitas Vaccinex, Inc.|VCNX - Utang jangka dawa marang ekuitas|Utang jangka cendhak marang ekuitas Vaccinex, Inc.|VCNX - Utang kumulatif perusahaan|Utang-utang marang kapitalisasi buku Vaccinex|VCNX - Tanggungan jangka dawa|Kewajiban jangka cendhak perusahaan Vaccinex|Indikator likuiditas cepet vaccinex.com
- informasi bathi lan kelipatan valuasi:
VCNX - Bathi pungkasan
Analisis fundamental perusahaan:Vaccinex, VCNX
Barang utama Vaccinex, Inc.

Developing innovative antibodies to combat neurodegeneration requires colossal clinical trial expenditures, making the analysis of the debt-to-equity ratio critical for assessing the financial stability of Vaccinex, Inc. (VCNX). This ratio compares total liabilities to shareholders' equity, allowing investors to determine the business's level of dependence on creditors and the bankruptcy risks in the absence of strategic partnerships.

Pesaing Vaccinex, Inc. (VCNX)

Utang marang Ekuitas ImmunityBio|Utang marang Modal Immunocore Holdings IMCR|Utang marang Ekuitas Janux Pharma (JANX)|Arcus Corp - Rasio Utang marang Ekuitas|Total Utang marang Modal ZYME (Zymeworks Inc.)|TNGX - Rasio Total Utang marang Ekuitas|IOVA - Utang marang Ekuitas|Utang marang Modal Immatics NV|Xencor Corp (XNCR) - Utang marang Ekuitas|CMPX (Compass Therapeutics Corp) - Utang marang Ekuitas|Utang marang Ekuitas Replimune Group, Inc.|Utang marang Modal lyell.com LYEL|Total Utang marang Modal IPHA|pyxisoncology.com (PYXS) - Rasio Utang marang Modal|Compugen - Rasio Total Utang marang Ekuitas|IO Biotech Inc. (IOBT) - Utang marang Modal|STRO: Rasio Total Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi INKT (minktherapeutics.com)|HOWL: Total Utang marang Modal|IMMX - Koefisien Total Utang marang Modal|Utang marang Ekuitas ALX Oncology Holdings|Rasio Total Utang marang Ekuitas cuebiopharma.com (CUE)|Utang marang Ekuitas PDS Biotechnology (PDSB)|Rasio Total Utang marang Ekuitas sonnetbio.com SONN|MAIA Biotechnology, Inc. - Rasio Total Utang marang Ekuitas|Total Utang marang Modal Liminatus Pharma Inc. LIMN|LVTX - Utang marang Ekuitas|NXTC (NextCure Corporation) - Rasio Utang marang Ekuitas|leaptx.com (LPTX) - Utang marang Ekuitas|Utang marang Modal Intensity Therapeutics, Inc. (INTS)|Rasio Total Utang marang Ekuitas SNSE|TOVX - Rasio Utang marang Modal|Rasio Total Utang marang Ekuitas GRTS (Gritstone bio, Inc.)|Utang Agregat marang Modal KA|Total Utang marang Modal NEXI (NexImmune, Inc.)|Rasio Kabeh Utang marang Dana Pribadi TSBX|Harpoon Therapeutics, Inc. - Total Utang marang Modal